These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35128787)

  • 1. Anhydrous Nucleic Acid Nanoparticles for Storage and Handling at Broad Range of Temperatures.
    Tran AN; Chandler M; Halman J; Beasock D; Fessler A; McKeough RQ; Lam PA; Furr DP; Wang J; Cedrone E; Dobrovolskaia MA; Dokholyan NV; Trammell SR; Afonin KA
    Small; 2022 Apr; 18(13):e2104814. PubMed ID: 35128787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Application of Light-Assisted Drying to the Thermal Stabilization of Nucleic Acid Nanoparticles.
    Anh Lam P; Furr DP; Tran A; McKeough RQ; Beasock D; Chandler M; Afonin KA; Trammell SR
    Biopreserv Biobank; 2022 Oct; 20(5):451-460. PubMed ID: 36067075
    [No Abstract]   [Full Text] [Related]  

  • 3. Light-Assisted Drying for the Thermal Stabilization of Nucleic Acid Nanoparticles and Other Biologics.
    Trammell SR
    Methods Mol Biol; 2023; 2709():117-130. PubMed ID: 37572276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs).
    Ke W; Afonin KA
    Adv Drug Deliv Rev; 2021 Sep; 176():113835. PubMed ID: 34144087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects.
    Johnson MB; Chandler M; Afonin KA
    Adv Drug Deliv Rev; 2021 Jun; 173():427-438. PubMed ID: 33857556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosome mediated delivery of functional nucleic acid nanoparticles (NANPs).
    Nordmeier S; Ke W; Afonin KA; Portnoy V
    Nanomedicine; 2020 Nov; 30():102285. PubMed ID: 32781137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Break to Build: Isothermal Assembly of Nucleic Acid Nanoparticles (NANPs)
    Beasock D; Ha A; Halman J; Panigaj M; Wang J; Dokholyan NV; Afonin KA
    Bioconjug Chem; 2023 Jun; 34(6):1139-1146. PubMed ID: 37293781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cationic amphiphilic co-polymer as a carrier of nucleic acid nanoparticles (Nanps) for controlled gene silencing, immunostimulation, and biodistribution.
    Halman JR; Kim KT; Gwak SJ; Pace R; Johnson MB; Chandler MR; Rackley L; Viard M; Marriott I; Lee JS; Afonin KA
    Nanomedicine; 2020 Jan; 23():102094. PubMed ID: 31669854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation.
    Afonin KA; Dobrovolskaia MA; Ke W; Grodzinski P; Bathe M
    Adv Drug Deliv Rev; 2022 Feb; 181():114081. PubMed ID: 34915069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Intracellular Compartmentalization of RNA Nanostructures.
    Radwan Y; Afonin KA; Johnson MB
    Methods Mol Biol; 2023; 2709():211-228. PubMed ID: 37572283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial Immune Cell, AI-cell, a New Tool to Predict Interferon Production by Peripheral Blood Monocytes in Response to Nucleic Acid Nanoparticles.
    Chandler M; Jain S; Halman J; Hong E; Dobrovolskaia MA; Zakharov AV; Afonin KA
    Small; 2022 Nov; 18(46):e2204941. PubMed ID: 36216772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-Like Receptor-Mediated Recognition of Nucleic Acid Nanoparticles (NANPs) in Human Primary Blood Cells.
    Hong E; Halman JR; Shah A; Cedrone E; Truong N; Afonin KA; Dobrovolskaia MA
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30897721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier.
    Avila YI; Chandler M; Cedrone E; Newton HS; Richardson M; Xu J; Clogston JD; Liptrott NJ; Afonin KA; Dobrovolskaia MA
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33513786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology.
    Afonin KA; Dobrovolskaia MA; Church G; Bathe M
    ACS Nano; 2020 Aug; 14(8):9221-9227. PubMed ID: 32706238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting Functional Biological Interactions Using Modular RNA Nanoparticles.
    Klotz K; Radwan Y; Chakrabarti K
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminating Immunorecognition Pathways Activated by RNA Nanostructures.
    Danai L; Johnson MB; Afonin KA
    Methods Mol Biol; 2023; 2709():229-240. PubMed ID: 37572284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smart-Responsive Nucleic Acid Nanoparticles (NANPs) with the Potential to Modulate Immune Behavior.
    Chandler M; Afonin KA
    Nanomaterials (Basel); 2019 Apr; 9(4):. PubMed ID: 31013847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.
    Juneja R; Vadarevu H; Halman J; Tarannum M; Rackley L; Dobbs J; Marquez J; Chandler M; Afonin K; Vivero-Escoto JL
    ACS Appl Mater Interfaces; 2020 Sep; 12(35):38873-38886. PubMed ID: 32805923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and Composition Define Immunorecognition of Nucleic Acid Nanoparticles.
    Hong E; Halman JR; Shah AB; Khisamutdinov EF; Dobrovolskaia MA; Afonin KA
    Nano Lett; 2018 Jul; 18(7):4309-4321. PubMed ID: 29894623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology.
    Panigaj M; Johnson MB; Ke W; McMillan J; Goncharova EA; Chandler M; Afonin KA
    ACS Nano; 2019 Nov; 13(11):12301-12321. PubMed ID: 31664817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.